drugset / Trial / NCT01017276

A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal Dialysis

NCT01017276

Phase 3 Completed 35 enrolled Astellas Pharma Inc
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a multi-center, open-labeled, non-comparative study to examine the safety and efficacy of ASP1585 in chronic kidney disease and hyperphosphatemia patients on peritoneal dialysis.

Timeline

Start
2009-11
Primary completion
2010-09
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Bixalomer Small molecule Oral